LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER - PR Newswire
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced detailed results from the global Phase 3 CodeBreaK 200 trial, which showed once-daily oral...
At 1-Year, Progression-Free Survival was 25% for LUMAKRAS Versus 10% for Docetaxel
LUMAKRAS Met Key Secondary Endpoint of Objective Response Rate
THOUSAND OAKS, Calif., Sept. 11, 2022 /PRNewswire/ … [+22241 chars]
Read More
Other Stories in Business
- Gulf War veteran executed for 1998 quadruple murder despite claims of mental illness
- Guardant Health (GH) Reports Strong Q1 2025 Revenue Growth
- Connecting Asia's startup ecosystem
- Connecting Asia's startup ecosystem
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- Business First Bancshares, Inc. (BFST) Q1 2025 Earnings Call Transcript
